Market news
17.03.2021, 14:49

WHO recommends AstraZeneca vaccinations continue

CNBC reports that the World Health Organization said that coronavirus vaccination rollouts using the AstraZeneca-Oxford University shot should continue while it carries out a safety review.

The latest guidance from the global public health body comes after a raft of European countries announced that they would suspend use of the shot over concerns that it could be linked to reported cases of blood clots in the region.

On Wednesday, the WHO issued a statement in which it said that “vaccination against COVID-19 will not reduce illness or deaths from other causes.”

It said that while it was routine for countries to signal potential adverse events following immunization, particularly in mass vaccination campaigns, “this does not necessarily mean that the events are linked to vaccination itself.”

Nonetheless, it added, “it is good practice to investigate them. It also shows that the surveillance system works and that effective controls are in place.”

© 2000-2021. All rights reserved.

This site is managed by Teletrade D.J. Limited 20599 IBC 2012 (First Floor, First St. Vincent Bank Ltd Building, James Street, Kingstown, St. Vincent and the Grenadines).

The information on this website is for informational purposes only and does not constitute any investment advice.

AML Website Summary

Risk Disclosure

Making transactions on financial markets with marginal financial instruments opens up wide possibilities and allows investors who are willing to take risks to earn high profits, carrying a potentially high risk of losses at the same time. Therefore you should responsibly approach the issue of choosing the appropriate investment strategy, taking the available resources into account, before starting trading.

Privacy Policy

Use of the information: full or partial use of materials from this website must always be referenced to TeleTrade as the source of information. Use of the materials on the Internet must be accompanied by a hyperlink to Automatic import of materials and information from this website is prohibited.

Please contact our PR department if you have any questions or need assistance at

Live Chat E-mail
Choose your language / location